Therefore, the most promising path forward in CML treatment will require identification of the specific off-target mechanism(s) of NAD and utilization of this information to design the next generation of ABL1 TKIs. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.